[Clinical and experimental study on effect of shuanghuang shengbai granule on myelosuppression induced by chemotherapy and ultrastructure observation of bone marrow in mice].
OBJECTIVE
To observe the leukocyte increasing effects of Shaunghuang Shengbai Granule (SHSBG) in tumor patients treated by chemotherapy (CT) and its function on bone marrow hematopoietic microenvironment in mice.


METHODS
Patients of non-small-cell lung cancer and breast, gastric or intestinal cancer, who were retreated with CT, were enrolled and divided into 4 groups randomly. The 28 cases in the treated group 1 received SHSBG and CT simultaneously. The 27 cases in the treated group 2 also received firstly CT, and SHSBG started when WBC count lowered to less than 4 x 10(9)/L after CT. The control group 1 and 2 (n = 33 and n = 24) was treated by the method similar to that applied to the treated group 1 and 2 respectively but with Rubidate instead of SHSBG. Experimental study of observing bone marrow ultrastructure in mice was also conducted with electron microscopy.


RESULTS
The total leukocyte increasing effective rate occurred in the treated group 1 was 75.00%, that in the treated group 2 was 88.89%, in the control group 1 was 54.55% and in the control group 2 was 58.33%. There was significant difference between the treated groups and the control groups (P < 0.01). Experimental study showed that SHSBG has good bone marrow hematopoietic microenvironmental protecting and improving effect in mice.


CONCLUSIONS
SHSBG has obvious protecting and treating effect on CT caused bone marrow suppression in tumor patients.
Xu
Z Y
ZY
Department of Oncology, Longhua Hospital, Shanghai University of TCM, Shanghai 200032.
Zhu
Y W
YW
Zhou
W D
WD
D000328:Adult; D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006412:Hematopoietic Stem Cells / Q000648:ultrastructure; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects; D008517:Phytotherapy; D014747:Vinblastine / Q000009:adverse effects
D004365:Drugs, Chinese Herbal; D008937:Mitomycins; C000617180:shuanghuang shengbai; D014747:Vinblastine; D002945:Cisplatin